Holen Sie sich die Stockscreener-App
7.01
3.44%
-0.25
Vorhandelsmarkt:
7.01
Schlusskurs vom Vortag:
$7.26
Offen:
$7.255
24-Stunden-Volumen:
2.34M
Relative Volume:
0.59
Marktkapitalisierung:
$1.70B
Einnahmen:
$386.15M
Nettoeinkommen (Verlust:
$-56.39M
KGV:
-30.48
EPS:
-0.23
Netto-Cashflow:
$-55.19M
1W Leistung:
+0.14%
1M Leistung:
-4.76%
6M Leistung:
+25.18%
1J Leistung:
+28.62%
1-Tages-Spanne:
$6.96
$7.33
1-Wochen-Bereich:
$6.96
$7.43
52-Wochen-Spanne:
$3.21
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Firmenname
Ardelyx Inc
Sektor
Branche
Telefon
510-745-7047
Adresse
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
7.01 | 1.76B | 386.15M | -56.39M | -55.19M | -0.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-09-03 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-02 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2025-03-04 | Eingeleitet | BTIG Research | Buy |
| 2024-11-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2023-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-25 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-11-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Herabstufung | Jefferies | Buy → Hold |
| 2021-07-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-23 | Eingeleitet | Wedbush | Outperform |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Fortgesetzt | Citigroup | Buy |
| 2020-02-18 | Fortgesetzt | Jefferies | Buy |
| 2020-02-12 | Eingeleitet | Citigroup | Buy |
| 2020-02-10 | Eingeleitet | Cowen | Outperform |
| 2019-04-08 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-24 | Eingeleitet | Jefferies | Buy |
| 2018-03-19 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-29 | Bestätigt | Citigroup | Buy |
| 2017-11-22 | Bestätigt | Ladenburg Thalmann | Buy |
| 2017-10-17 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-03-31 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-09 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
Ardelyx (ARDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Ardelyx (ARDX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Ardelyx, Inc. (ARDX) Reports Strong 2025 Revenue Growth, Updates 2026 Outlook - Insider Monkey
10 Best Long Term Healthcare Stocks to Buy - Insider Monkey
Ardelyx, Inc. (ARDX) gains TD analysts support ahead of Q4 results - MSN
Trend Report: Is Ardelyx Inc stock a buy or sell2025 Geopolitical Influence & Reliable Price Breakout Alerts - baoquankhu1.vn
Ardelyx Patent Extends Tenapanor Franchise Planning Horizon To 2042 - Yahoo Finance
Ardelyx, Inc. to Host Conference Call for 2025 Financial Results and Business Update - Quiver Quantitative
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 - The Manila Times
Assessing Ardelyx (ARDX) Valuation After Patent Extension And Pipeline Progress - simplywall.st
Ardelyx receives new patent for Tenapanor - Yahoo Finance
Raymond James reiterates Strong Buy on Ardelyx stock after patent news - Investing.com UK
Raymond James reiterates Strong Buy on Ardelyx stock after patent news By Investing.com - Investing.com South Africa
Ardelyx (ARDX) Secures New Patent for Tenapanor Formulations - GuruFocus
Ardelyx Receives New Patent for Tenapanor - The Manila Times
Ardelyx, Inc. Secures U.S. Patent for Tenapanor Formulations, Expiring November 2042 - Quiver Quantitative
New patent shields Ardelyx gut drugs IBSRELA, XPHOZAH until 2042 - stocktitan.net
Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results - Insider Monkey
Jefferies remains a buy on Ardelyx (ARDX) - MSN
Jefferies Remains a Buy on Ardelyx (ARDX) - Finviz
How Ardelyx’s Phase 3 IBSRELA Trial in Chronic Constipation Has Changed Its Investment Story At Ardelyx (ARDX) - simplywall.st
Y Intercept Hong Kong Ltd Grows Stock Position in Ardelyx, Inc. $ARDX - MarketBeat
Ardelyx (NASDAQ:ARDX) Earns Buy Rating from BTIG Research - MarketBeat
BTIG Reiterates Buy Rating on Ardelyx (ARDX) with Stable Price T - GuruFocus
Ardelyx begins phase 3 trial of IBSRELA for chronic constipation By Investing.com - Investing.com South Africa
Ardelyx Draws Zydus Interest As IBSRELA Trial And Valuation Gain Focus - Sahm
Is Ardelyx (ARDX) Pricing Reflect Its Strong Multi Year Share Price Performance - Yahoo Finance
How Ardelyx’s Phase 3 ACCEL Trial for IBSRELA in CIC Will Impact Ardelyx (ARDX) Investors - Yahoo Finance
Ardelyx Says First Patient Dosed in Phase 3 Trial of Chronic Idiopathic Constipation Treatment - marketscreener.com
What analysts say about Ardelyx Inc. stockJuly 2025 Earnings & Safe Capital Allocation Plans - mfd.ru
Ardelyx begins phase 3 trial of IBSRELA for chronic constipation - Investing.com
Ardelyx (ARDX) Begins Dosing in Phase 3 Trial for IBSRELA - GuruFocus
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA - The Manila Times
Ardelyx IncEnrollment Expected Throughout 2026, Topline Data in 2027 - marketscreener.com
New 700-patient constipation drug trial begins, targeting 34M adults - stocktitan.net
Is It Too Late To Consider Ardelyx (ARDX) After The Recent Share Price Surge? - simplywall.st
All You Need to Know About Ardelyx (ARDX) Rating Upgrade to Buy - Yahoo Finance
Palisades Investment Partners LLC Cuts Position in Ardelyx, Inc. $ARDX - MarketBeat
AIGH Capital Management LLC Makes New Investment in Ardelyx, Inc. $ARDX - MarketBeat
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Ardelyx (ARDX) and AxoGen (AXGN) - The Globe and Mail
Ardelyx Investors Appeal Dismissal of Medicare Program Lawsuit - Bloomberg Law News
Ardelyx responds to Zydus Lifesciences acquisition reports - cnbctv18.com
Ardelyx stock hits 52-week high at 8.06 USD By Investing.com - Investing.com Australia
Finanzdaten der Ardelyx Inc-Aktie (ARDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):